Business
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort –Favorable safety profile with six cases of mild, manageable grade 1 cytokine release syndrome (CRS) across all patients treated to date, all of which occurred in the 15 mg/kg dose cohort –Data support advancement to Phase 2 studies, currently being planned
About this update from Sensei Biotherapeutics, Inc.
[{"type":"image","alt":"Sensei Biotherapeutics","displaySize":"","headline":null,"caption":"Sensei Biotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":111,"url":"https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tSVB9mWPe6cbY7LRif6RFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405","width":300,"height":111}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort –","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Favorable safety profile with six cases of mild, manageable grade 1 cytokine release syndrome (CRS) across all patients treated to date, all of which occurred in the 15 mg/kg dose cohort –","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"Data support advancement to Phase 2 studies, currently being planned in Non-Small Cell Lung Cancer and Merkel Cell Carcinoma –","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Sensei to host investor webcast Monday, October 20th at 8:00 AM ET –","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":626,"olType":false},{"type":"text","content":"BOSTON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug (formerly SNS-101), a conditionally active monoclonal antibody targeting VISTA (V-domain Ig suppressor of T cell activation). The data will be shared today during a mini oral session at the ESMO Congress 2025.","length":532,"tagName":"p"},{"type":"text","content":"The Phase 1 dose expansion is a multi-center, open-label study evaluating solnerstotug as monotherapy and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor. The study enrolled patien...